文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

桔梗对接受蒽环类化疗的早期乳腺癌患者的心脏保护作用:随机对照试验研究方案

Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-08-22

本研究为单中心、双盲、随机、安慰剂对照、平行组试验,计划纳入120例接受蒽环类化疗的早期乳腺癌患者,按1:1随机分配接受桔梗颗粒或安慰剂颗粒每日两次、共12周,主要结局为心力衰竭(临床或亚临床),次要结局包括全因死亡、心脏死亡、心电图、左室舒张功能、组织多普勒纵向收缩应变与速度、心肌生物标志物等,评估心脏保护作用与安全性。

要点

  • 拟纳入120例早期乳腺癌接受蒽环类化疗患者,1:1随机分入桔梗颗粒组或安慰剂组。
  • 干预为桔梗颗粒或安慰剂颗粒每日两次、共12周,主要结局为临床或亚临床心力衰竭。
  • 次要结局包括全因死亡、心脏死亡、心电图、左室舒张功能、组织多普勒指标及心肌生物标志物。

核心结论

  • 本试验旨在评估桔梗颗粒相比安慰剂颗粒在接受蒽环类化疗的早期乳腺癌患者中的心脏保护作用与安全性。
  • 作者表示这是首个评估桔梗在该人群中心脏保护作用与安全性的临床试验,并用于评估未来开展更大规模临床试验的可行性。

研究设计与样本

  • 单中心、双盲、随机、安慰剂对照、平行组试验,计划纳入120例接受蒽环类化疗的早期乳腺癌患者,按1:1比例随机分配。

主要发现

  • 本稿为研究方案,未报告试验结果。

关键数值与推荐

  • 干预:桔梗颗粒或安慰剂颗粒,每日两次,共12周。
  • 主要结局:心力衰竭(临床或亚临床)。
  • 次要结局:全因死亡、心脏死亡、心电图表现、左室舒张功能、组织多普勒成像测量的纵向收缩应变与速度、心肌生物标志物如肌钙蛋白I(TnI)、脑钠肽(BNP)和肌酸激酶同工酶(CK-MB)。
  • 评估时间点:基线(随机化前)及随机化后3、6、9、12、16、20周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anthracyclines, alone or in combination with other drugs, are among the most effective chemotherapeutic agents to treat breast cancer both in the adjuvant and neoadjuvant setting. Unfortunately, anthracycline-associated dose-dependent cardiotoxicity is a limiting factor in clinical use. Extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity. However, most cardioprotective agents have shown little effect in clinical trials. Herbal medicines are pure, natural substances that have been used for centuries in many countries, including China. This trial aims to evaluate the cardioprotective effects and safety of Platycodon grandiflorum granules compared to placebo granules in patients with early breast cancer receiving anthracycline-based chemotherapy. METHOD/DESIGN: This study is a single-center, double-blinded, randomized, placebo-controlled, parallel-group trial. A total of 120 patients will be randomly allocated in a 1:1 ratio to receive either P. grandiflorum granules or placebo granules twice daily for 12 weeks. The primary outcome is heart failure (either clinical or subclinical). The secondary outcomes include all-cause mortality, cardiac death, electrocardiogram (ECG) findings, left ventricular diastolic function, longitudinal systolic strain and velocities measured by tissue Doppler imaging, cardiac biomarkers, such as troponin I (TnI), brain natriuretic peptide (BNP), and creatine kinase isoenzymes (CK-MB). Assessments will be performed at baseline (before randomization) and 3, 6, 9, 12, 16, and 20 weeks after randomization. DISCUSSION: This will be the first clinical trial to evaluate the cardioprotective effects and safety of P. grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy. We are also performing this trial to assess the feasibility of a larger-scale clinical trial in the future. TRAIL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IPR-16009256 . Registered on 23 September 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hao W, Liu S, Qin Y, et al. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28830541. doi:10.1186/s13063-017-2140-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。